Detalhe da pesquisa
1.
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Cancer
; 121(7): 1056-63, 2015 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25411085
2.
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 32(1): 87-93, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23525756
3.
Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models.
Target Oncol
; 14(5): 603-611, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31506873
4.
Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers.
Clin Ther
; 40(11): 1855-1867, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30458930
5.
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Prostate
; 61(3): 228-35, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15368474